[go: up one dir, main page]

WO2019151964A3 - Orally disintegrating formulations of saxagliptin - Google Patents

Orally disintegrating formulations of saxagliptin Download PDF

Info

Publication number
WO2019151964A3
WO2019151964A3 PCT/TR2018/050869 TR2018050869W WO2019151964A3 WO 2019151964 A3 WO2019151964 A3 WO 2019151964A3 TR 2018050869 W TR2018050869 W TR 2018050869W WO 2019151964 A3 WO2019151964 A3 WO 2019151964A3
Authority
WO
WIPO (PCT)
Prior art keywords
saxagliptin
orally disintegrating
disintegrating formulations
pharmaceutically acceptable
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050869
Other languages
French (fr)
Other versions
WO2019151964A2 (en
Inventor
Ali TÜRKYILMAZ
Gülcan KAPLAN
Nur PEHLIVAN AKALIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2019151964A2 publication Critical patent/WO2019151964A2/en
Publication of WO2019151964A3 publication Critical patent/WO2019151964A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an orally disintegrating pharmaceutical formulation comprising saxagliptin or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
PCT/TR2018/050869 2017-12-26 2018-12-24 Orally disintegrating formulations of saxagliptin Ceased WO2019151964A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21700A TR201721700A2 (en) 2017-12-26 2017-12-26 DISTRIBUTED FORMULATIONS OF SAXAGLIPT IN THE MOUTH
TR2017/21700 2017-12-26

Publications (2)

Publication Number Publication Date
WO2019151964A2 WO2019151964A2 (en) 2019-08-08
WO2019151964A3 true WO2019151964A3 (en) 2019-10-31

Family

ID=67479379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050869 Ceased WO2019151964A2 (en) 2017-12-26 2018-12-24 Orally disintegrating formulations of saxagliptin

Country Status (2)

Country Link
TR (1) TR201721700A2 (en)
WO (1) WO2019151964A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202009724A2 (en) * 2020-06-23 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi FORMULATION OF CYTAGLIPTIN IN ORAL DISTRIBUTION TABLET
CN114869904B (en) * 2022-05-09 2023-10-20 广州汉光药业股份有限公司 Compound vitamin self-emulsifying drug delivery system and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JYOTHI RANI L ET AL.: "Formulation and Evaluation of Fast Dissolving Delivery System of Saxagliptin", INTERNATIONAL JOURNAL OF CHEMISTRY AND PHARMACEUTICAL SCIENCES, vol. 2, no. 5, 2014, pages 862 - 869 *
JYOTHI RANI L. ET AL.: "Formulation and Evaluation of Fast Dissolving Tablets of Saxagliptin", INTERNATIONAL JOURNAL OF BIOLOGICAL & PHARMACEUTICAL RESEARCH, vol. 5, no. 5, 2014, pages 408 - 414, XP055648067 *
SHRIVASTAVA PRIYANKA ET AL.: "A Review Article On: Superdisintegrants", INTERNATIONAL JOURNAL OF DRUG RESEARCH AND TECHNOLOGY, vol. 3, no. 4, 2013, pages 76 - 87, XP055648075 *
V. T. ISWARIYA ET AL.: "Formulation and Evaluation of Oro Dispersive Tablets of Saxagliptin", INT. J. PHARM. SCI. REV. RES, vol. 30, no. 2, 42, January 2015 (2015-01-01) - February 2015 (2015-02-01), pages 230 - 234, XP055648064 *

Also Published As

Publication number Publication date
WO2019151964A2 (en) 2019-08-08
TR201721700A2 (en) 2019-07-22

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
EP4233846A3 (en) Pharmaceutical formulations
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
WO2017037594A3 (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
EP3684371A4 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
HK1254343A1 (en) Pharmaceutical formulations
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
EP3400964A4 (en) Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof
EA036036B1 (en) Compositions comprising cyclosporin
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
EP4606432A3 (en) Formulations of an axl/mer inhibitor
MX2022013450A (en) Pharmaceutical formulations.
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2019209217A3 (en) Modified release formulations of flurbiprofen
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2019221684A3 (en) The bilayer tablet formulation of fesoterodine
WO2020018053A3 (en) The tablet comprising dasatinib
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors
EP3870167A4 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18903994

Country of ref document: EP

Kind code of ref document: A2